Why Pancragen Stands Out
Pancragen — also written pancragene — is a synthetic tetrapeptide, Lys-Glu-Asp-Trp (KEDW), classified within the bioregulator family as pancreas-associated.
It has six published papers naming it directly. That is the largest compound-specific literature of any member of this family, and two of those papers are in old rhesus monkeys — the only non-human-primate work in the entire set.
Structurally it is also the most interesting comparison case available: KEDW is KED extended by a single tryptophan. One residue separates the family's best-documented compound from one with no literature at all.
Research use only. Supplied for laboratory research. Not for human or veterinary use. No marketing authorisation exists and no therapeutic claim is made.
Primate Studies
Two papers from the same group report on old female rhesus monkeys: correction of impaired glucose tolerance using the tetrapeptide (Goncharova et al., Adv Gerontol 2015, PMID 28509500) and the impact of the tetrapeptide on endocrine function of the pancreas in old monkeys (Goncharova et al., 2014, PMID 25946840).
Primate data is a genuine step up from rodent work in physiological proximity. It is not a substitute for a controlled human trial, and these are small-cohort ageing studies from one laboratory, not a programme.
Rodent and Cell Work
The rodent literature centres on experimental diabetes: an effect on blood glucose, capillary permeability and adhesion in rats with experimental diabetes mellitus (Khavinson et al., Bull Exp Biol Med 2007, PMID 18642713) and an effect on functional morphology of the pancreas in the same model (Kvetnoi et al., 2007, PMID 18225766).
At cell level, a study reports effects on the differentiation of pancreatic cells during ageing (Khavinson et al., Bull Exp Biol Med 2013, PMID 23486591). A further paper discusses prospects for correction of metabolic disorders in elderly people (Korkushko et al., 2011, PMID 22448364) — read the design carefully, since "prospects" papers in this literature are frequently discussion rather than controlled trial.
Reading the Evidence
Convergence across levels is the real strength. Cell differentiation, rodent physiology and primate glucose handling point the same direction. That is a better evidentiary shape than six papers at one level would be.
The concentration caveat still applies. The primate work is from a single group, and most of the set is from the originating programme.
Ageing models are not disease models. These are studies in old animals, not in a human metabolic condition.
No amount is established for any species or context, and none is offered here.
Structure and Handling
- Sequence. Lys-Glu-Asp-Trp (KEDW), tetrapeptide.
- Formula. C26H36N6O9, 576.61 g/mol.
- Form. Lyophilised powder, ≥98% purity, third-party certificate of analysis per batch.
- Storage. Sealed vial at −20 °C, protected from light; reconstituted solution at 2–8 °C.
- Reconstitution. Bacteriostatic water down the vial wall, never onto the powder cake. Do not shake. See the reconstitution calculator.
The catalog record for this compound previously carried a molecular formula inconsistent with the stated sequence. It has been corrected against the sequence and verified. If you sourced material against the earlier figure, check the certificate of analysis for the batch you hold.
Related Compounds
Vesugen/Vesilute (KED) is Pancragen minus the tryptophan and has no compound-specific literature — a useful contrast if sequence-length effects are the question. See the bioregulator overview for the full family.
Research Studies at a Glance
The six published papers naming Pancragen (KEDW) directly span three experimental models — non-human primate, rodent, and isolated cell — and address outcomes ranging from glucose homeostasis to pancreatic morphology and cell differentiation. The table below maps each study to its key variables. No blinded, placebo-controlled human trial appears in this record; the primate work is the closest available physiological proxy, and it originates from a single research group at the St. Petersburg Institute of Bioregulation and Gerontology. Independent replication has not been reported in the indexed literature.
| Study (year) | Model | Reported dose / route | Primary outcome measured | Key finding | Ref |
|---|---|---|---|---|---|
| Goncharova et al. (2015) | Old female rhesus monkeys (Macaca mulatta) | Not disclosed in abstract; subcutaneous reported by group convention | Glucose tolerance (GTT) | Impaired glucose tolerance reported as corrected following tetrapeptide administration | [1] |
| Goncharova et al. (2014) | Old female rhesus monkeys | Not disclosed in abstract | Endocrine function markers, pancreatic hormone profiles | Modulation of endocrine pancreatic function observed in aged animals | [2] |
| Khavinson et al. (2007) | Rat, experimental diabetes mellitus (streptozotocin model) | Not disclosed in abstract | Blood glucose, capillary permeability, cell adhesion | Reductions in blood glucose and capillary permeability reported; adhesion parameters altered | [3] |
| Kvetnoi et al. (2007) | Rat, experimental diabetes mellitus | Not disclosed in abstract | Pancreatic functional morphology (histology) | Structural changes in pancreatic tissue reported following peptide treatment | [4] |
| Khavinson et al. (2013) | Isolated pancreatic cells, ageing model (in vitro) | In vitro; concentration not recoverable from abstract | Cell differentiation markers during ageing | Effects on differentiation programme observed at cell level | [5] |
| Korkushko et al. (2011) | Review / clinical perspective (elderly cohort context) | N/A — prospective discussion | Metabolic disorder correction in elderly subjects | Prospects for bioregulator use in age-related metabolic disruption discussed; KEDW cited among candidates | [6] |
Dose and route data are not fully recoverable from English-language abstracts; full-text sources in Russian should be consulted for experimental detail. Outcomes in the primate and rodent rows are reported findings, not established effects. The 2011 entry [6] is a perspective article and should not be read as an independent replication.
Proposed Molecular Mechanism: Short Peptide–Gene Interaction
The Khavinson group's broader theoretical framework — applied to KEDW as to other tetrapeptides in this family — proposes that short peptides interact directly with double-stranded DNA in a sequence-complementary manner, binding to promoter regions of target genes and modulating transcription. Under this model, a tetrapeptide of defined sequence would preferentially associate with a cognate DNA motif, upregulating expression of tissue-specific proteins whose promoters carry that motif. For a pancreas-associated peptide, the proposed targets are genes involved in insulin biosynthesis, beta-cell maintenance, and glucose-sensing machinery.
This mechanism has not, to this reviewer's knowledge, been validated for KEDW specifically by crystallography, chromatin immunoprecipitation, or reporter-gene assay in an independent laboratory. The cell-level differentiation data [5] are consistent with a transcriptional effect, but consistency is not confirmation. The rodent data [3],[4] demonstrate downstream metabolic and morphological changes without resolving whether the upstream event is direct DNA binding, receptor-mediated signalling, or an indirect consequence of altered tissue environment in a diabetic model.
From a pharmacodynamic standpoint, two features of KEDW are worth noting. First, the C-terminal tryptophan residue — absent in the KED tripeptide — introduces an aromatic, planar side chain that could participate in stacking interactions with nucleobases, a property invoked in the group's general model of peptide–DNA complementarity. Whether this residue is necessary for the reported pancreatic specificity has not been tested by alanine-scanning mutagenesis or by direct comparison of KEDW versus KED in the same experimental system. Second, peptides of this length are subject to rapid proteolysis under physiological conditions; if direct DNA interaction is the operative mechanism, cellular entry and nuclear localisation would be prerequisite steps that have not been directly demonstrated for KEDW. The mechanism, as currently supported, is best classified as proposed: plausible given the structural chemistry and consistent with the downstream observations, but not yet independently tested at the mechanistic level.
Structural Comparison: KEDW Versus KED and Related Bioregulators
Understanding Pancragen's position within the bioregulator family requires comparing it structurally with its nearest neighbours. The KED tripeptide (Lys-Glu-Asp) is the parent sequence; KEDW extends it by a single tryptophan at the C-terminus. No published study directly compares KEDW and KED in the same experimental model, so claims about the functional consequence of that extension are inferential. The table below places KEDW alongside four structurally or functionally proximal bioregulators for which some indexed literature exists.
| Compound | Sequence | Residues | Nominal target tissue | Highest-model evidence | Independent replication? |
|---|---|---|---|---|---|
| Pancragen (KEDW) | Lys-Glu-Asp-Trp | 4 | Pancreas | Non-human primate [1],[2] | Not identified in indexed literature |
| KED | Lys-Glu-Asp | 3 | Pancreas (proposed) | Not identified; no compound-specific indexed papers found | N/A |
| Epithalon (AEDG) | Ala-Glu-Asp-Gly | 4 | Pineal / systemic ageing | Human observational (same group) | Limited; mostly single-group |
| Bronchogen (AEDL) | Ala-Glu-Asp-Leu | 4 | Bronchial epithelium | Rodent / cell | Not identified |
| Cortagen (AEDG-extended) | Ala-Glu-Asp-Arg | 4 | Cortex / nervous tissue | Rodent | Not identified |
Sequences and tissue assignments are drawn from the Khavinson group's published classifications. Molecular weights are not tabulated here because full-text sources should be consulted to confirm each sequence before mass calculations are used in research protocols.
Several points follow from this comparison. First, Pancragen's distinction within the family is empirical, not just positional: it has the most indexed studies and the highest-model evidence by a significant margin. Second, the one-residue difference between KED and KEDW is structurally non-trivial — tryptophan has the largest side chain of any standard amino acid and the only bicyclic aromatic ring system — yet its functional necessity has never been tested in a controlled experiment. Third, the family-wide pattern of single-group provenance is a recognised limitation: publication by one laboratory is a starting point for a research programme, not its conclusion. Any laboratory considering KEDW as a research tool in a pancreatic model should treat the existing literature as preliminary and design experiments with appropriate controls, including sequence-scrambled and length-matched peptides, to begin to address the mechanism question the current record leaves open.
